We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 143.00 | 151.00 | 170.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2021 to Apr 2024
TIDMAMYT
RNS Number : 6397I
Amryt Pharma PLC
13 August 2021
GENERAL TEXT AMENDMENT
The following amendment has been made to the Holding(s) in Company announcement released on 10(th) August at 9.53am under RNS No 1441I.
The shareholding percentage (but not the total shares) has been updated to reflect the pre-Warrant Share Admission number of ordinary shares outstanding as of August 5.
All other details remain unchanged.
The full amended text is shown below.
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BKLTQ412
Issuer Name
AMRYT PHARMA PLC
UK or Non-UK Issuer
Non-UK
2. Reason for Notification
An event changing the breakdown of voting
3. Details of person subject to the notification obligation
Name
Athyrium Funds GP Holdings LLC
City of registered office (if applicable)
New York
Country of registered office (if applicable)
United States
4. Details of the shareholder
Hot Features
Premium
Name City of registered office Country of registered office
Athyrium Opportunities III Acquisition 2 LP Wilmington United States
=========================== ==============================
Athyrium Opportunities II Acquisition 2 LP Wilmington United States
=========================== ==============================
5. Date on which the threshold was crossed or reached
05-Aug-2021
6. Date on which Issuer notified
09-Aug-2021
7. Total positions of person(s) subject to the notification obligation
% of voting rights % of voting rights Total of both in % Total number of
attached to shares through financial (8.A + 8.B) voting rights held
(total of 8.A) instruments (total in issuer
of 8.B 1 + 8.B 2)
Resulting situation
on the date on
which threshold
was crossed or
reached 14.420000 0.000000 14.420000 44286346
====================== ====================== ====================== ======================
Position of
previous
notification (if
applicable)
====================== ====================== ====================== ======================
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares Number of direct Number of indirect % of direct voting % of indirect voting
ISIN code(if possible) voting rights (DTR5.1) voting rights rights (DTR5.1) rights (DTR5.2.1)
(DTR5.2.1)
GB00BKLTQ412 0 44286346 0.000000 14.420000
====================== ====================== ====================== ======================
Sub Total 8.A 44286346 14.420000%
============================================== ==============================================
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial Expiration date Exercise/conversion period Number of voting rights % of voting rights
instrument that may be acquired if
the instrument is
exercised/converted
Sub Total 8.B1
=========================================== ========================= ==================
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial Expiration date Exercise/conversion Physical or cash Number of voting % of voting rights
instrument period settlement rights
Sub Total 8.B2
========================================================= =================== ==================
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
Ultimate controlling Name of controlled % of voting rights if % of voting rights Total of both if it
person undertaking it equals or is through financial equals or is higher
higher than the instruments if it than the notifiable
notifiable threshold equals or is higher threshold
than the notifiable
threshold
Athyrium Funds GP
Jeffrey Ferrell Holdings LLC 14.420000 0.000000 14.420000
======================= ===================== ===================== ======================
Athyrium GP Holdings
Jeffrey Ferrell LLC 8.530000 0.000000 8.530000
======================= ===================== ===================== ======================
Athyrium
Opportunities
Jeffrey Ferrell Associates II LP 8.530000 0.000000 8.530000
======================= ===================== ===================== ======================
Athyrium
Opportunities II
Jeffrey Ferrell Acquisition 2 LP 8.530000 0.000000 8.530000
======================= ===================== ===================== ======================
Athyrium
Opportunities
Associates III GP
Jeffrey Ferrell LLC 5.890000 0.000000 5.890000
======================= ===================== ===================== ======================
Athyrium
Opportunities
Jeffrey Ferrell Associates III LP 5.890000 0.000000 5.890000
======================= ===================== ===================== ======================
Athyrium
Opportunities III
Jeffrey Ferrell Acquisition 2 LP 5.890000 0.000000 5.890000
======================= ===================== ===================== ======================
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
There are two chains of controlled undertakings, each controlled by Athyrium Funds GP Holdings LLC and, ultimately, Jeffrey Ferrell. As this was the first TR-1 report made through the ESS, there was a delay caused by registration. However, the Microsoft Word form of the notice was provided to the Issuer and the FCA email address on 09/08/2021.
12. Date of Completion
12-Aug-2021
13. Place Of Completion
New York, USA
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLUOSARAKUWAAR
(END) Dow Jones Newswires
August 13, 2021 08:23 ET (12:23 GMT)
1 Year Amryt Pharma Chart |
1 Month Amryt Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
